Answers are grounded in this paper and cite their sources.
Nutritional problems in adult patients with stage 5 chronic kidney disease (CKD) on dialysis can be classified into three categories: protein–energy wasting (PEW), obesity and diabetes. The prevalence of obesity in dialysis is strikingly increasing [1]. In a European cohort of incident dialysis patients from the Netherlands (1997–2004), the average BMI was found to be 25.3 kg/m2 showing that more than half of patients were overweight or obese [2]. The relationship of obesity with haemodialysis (HD) patient outcome is discussed in another article of this issue. Diabetes type 2 which prevalence was less 10% in French HD patients ten years ago [3] is now found in ~20% and associated with a 2-fold increase in mortality rate [4,5]. Its impact on nutritional status and on the responsiveness to nutritional therapies will be discussed below. The present article focuses on PEW in dialysis patients. The prevalence of PEW varies, according to the considered nutritional parameters, from 20% to 70% in adult HD patients [3] and from 18% to 56% in peritoneal dialysis (PD) patients [6]. PEW is an independent determinant of morbidity and mortality in HD as well as in PD patients. Twenty-five percent of HD patients exhibit a high-risk malnutrition as estimated from serum albumin and transthyretin (prealbumin) levels [3]. The yearly mortality rates of HD patients with low serum albumin and transthyretin are close to 25–30% [7]. Similar data were reported in PD patients. Because of the severity of PEW in dialysis, several guidelines from scientific societies recently addressed the monitoring of nutritional status, the nutritional requirements and the treatment of malnourished dialysis patients [8–12]. The present article focuses on the causes and management of PEW in dialysis patients. PEW in dialysis relates to both inadequate food intake and abnormal nutrient metabolism. In dialysis patients, the decrease in food intake is a major cause of PEW and mortality [13]. Multiple factors have been implicated (Table 1). Major causes of feeding restriction are comorbidities mainly cardiovascular disease and history of volume overload [6], hospitalizations, depression, low social status, dietary restrictions and multiple medical treatments [13]. The accumulation of uraemic toxic molecule such as the middle-size molecules can induce anorexia in a rat model [14]. Increased levels of satiety-inducing peptides and low levels of neuropeptide Y have been reported in PD patients [15]. Inflammatory cytokines, low nitric oxide and high leptin serum concentrations may participate in serotonin-induced anorexia [13]. Inadequate dialysis, as estimated by weekly dialysis time of less than 12 h and Kt/V index <1.1, is a documented cause of anorexia in HD patients [3]. In PD patients, residual renal function and dialysis adequacy are independently associated with protein and energy intake [16]. Low branched-chain amino acid (BCAA) and tryptophane transport across the blood–brain barrier may be responsible for abnormal synthesis of neurotransmitter and anorexia [17]. Causes of anorexia in haemodialysis and peritoneal dialysis patients Causes of anorexia in haemodialysis and peritoneal dialysis patients Concordingly, oral BCAA supplementation was shown to improve appetite in a placebo-controlled double-blind study on 28 malnourished patients with low BCAA levels and low protein and energy intakes [18]. Uraemia is associated with several gastrointestinal disturbances leading to a decrease in food intake, absorption and digestion: gastroparesia [19], exocrine pancreatic insufficiency and reduced mucosal enzyme activities [20,21]. Most studies on resting energy expenditure (REE) measurements in HD and PD patients reported REE values similar to that of controls [22–31]. In two studies, REE was found to be increased [32,33], and in one study in malnourished HD patients, REE was found to be decreased [34]. Regarding the determinants of REE, it was shown that severe hyperparathyroidism [26], elevated serum CRP [35] and serum IL-6 [29] were associated with increased REE. Residual renal function has a strong inverse association with REE, and the MIA syndrome, namely malnutrition, inflammation and atherosclerosis syndrome, is positively associated with REE. The increase in REE in patients with MIA syndrome appeared to be mediated via loss of residual renal function in PD patients [35]. HD sessions were shown to induce an increase in REE [33]. From these data obtained from HD and PD patients, it can be suggested that REE values are similar to those of controls and that dialysis procedure, inflammation and severe hyperparathyroidism can be responsible for increased energy expenditure. Insulin resistance is one of the metabolic features of CKD. Its mechanisms are not known completely. The lack of renal breakdown of gluco-regulatory peptides (insulin, glucagon, adrenalin), acidosis [36], inflammation [31] and uraemic toxins has been incriminated. A potential role of ghrelin in preserving insulin sensitivity has been suggested [31]. It was demonstrated that the non-oxidative glucose metabolism, i.e. the storage of glucose in the form of glycogen, is mainly altered in CKD-associated insulin resistance [23,24]. As a consequence, HD after a 12-h starvation, fat oxidation accounts for two-thirds of REE in HD patients as compared with 50% in controls [23,24]. Hypertriglyceridaemia is another characteristic of CKD [37]. The decrease in the lipid particule turnover, mainly due to reduced lipoprotein lipase, hepatic lipase and lecithin-cholesterol-acyl transferase activities, is associated with an increased lipid peroxidation [38]. Lipid metabolism abnormalities in dialysis patients also include a deficiency in essential fatty acids [39]. The role of carnitine deficiency is still debated [40]. In HD patients, plasma concentrations of AAs are characterized by a relative decrease in plasma serine and essential AAs except methionine, and an increase in citrulline and aspartate [41,42]. Tyrosine and histidine are considered as essential AAs in renal failure [43]. These disturbances of plasma AAs during CKD have been attributed to the abnormal handling of AAs not only in the kidneys but also in the hepatosplanchnic area. As a matter of fact, in conditions of normal kidney function, after a protein meal, the liver retains approximately 70% of AAs for protein synthesis (25%) and urea synthesis (45%) and releases 30% of them in the hepatic veins. The mixture of AAs released by the liver is characterized by enrichment with essential AAs and particularly with branched-chain AAs [44]; the quantitative loss of AAs through ureagenesis makes it possible for the liver to achieve a qualitative gain in the AA composition. During renal failure, such enrichment with essential AAs does not occur. These abnormalities of hepatosplanchnic AA metabolism, which can be reproduced by experimental acidosis [45], participate in the abnormal plasma AA pattern observed in CKD [44]. In non-dialysed CKD, a balanced reduction in both protein synthesis and catabolism has been reported [46,47]. Regarding protein metabolism, non-malnourished HD patients are characterized by an increase in whole-body and muscle protein turnover together with an increase in albumin and fibrinogen fractional synthesis rates [48,49]. Conversely, in 59 patients, a decrease in serum albumin during a 2-year follow-up was associated with a decrease in albumin synthesis. This response was associated with evidence of activation of the acute phase response (inflammation) but not with changes in protein intake [50]. The accelerated muscle protein turnover can compromise lean body mass (LBM) stores when protein intake is inadequate or during catabolic events. The main causes of reduced LBM in HD patients are given in Table 2. Among these catabolic factors, acidosis induces a cortisol-dependent stimulation of both muscle protein degradation, through the cytosolic ATP-ubiquitin-dependent proteolytic system and irreversible catabolism of branched-chain AAs [51]. Diabetes is associated with protein depletion, as reflected by decreased muscle mass, serum albumin and transthyretin [5]. Systemic inflammation, related to dialysis or not, has been reported in ~56% of HD and 48% of PD patients [52] (Table 3). The role of cytokine activation in increasing protein catabolism in dialysis patients has been underlined [53]. Abnormal anabolizing hormone status contributes to the loss of muscle mass: growth hormone (GH) resistance, androgen deficiency, decreased IGF-1 synthesis and transport [54–56]. Acidosis has been shown to be associated with the GH resistance and the decrease in IGF-1 synthesis [55]. Factors of lean body mass loss in haemodialysis and peritoneal dialysis patients Factors of lean body mass loss in haemodialysis and peritoneal dialysis patients Causes of inflammatory syndrome in dialysis patients Causes of inflammatory syndrome in dialysis patients A positive correlation was reported between renal residual function and subjective global assessment of nutritional status, normalized protein equivalent of total nitrogen appearance (nPNA) and serum albumin in PD patients [57,58]. Similarly, in children, adolescents and young adults on chronic HD treatment, renal residual function positively affects nutrition independently of HD efficiency and recombinant human GH (rhGH) treatment [59]. Dialysis dose is another recognized factor implicated in uraemic malnutrition. In 1610 HD patients on dialysis therapy for a long period and followed up during 30 months, higher serum albumin levels and a better survival were observed when high-flux dialysis membranes were used [60]. Improvements in numerous dialysis-associated metabolic variables, including body weight, nPNA and fat-free mass, have been reported after intensification of HD time [61]. The follow-up of nutritional parameters is mandatory in order to detect and treat malnourished HD patients. Table 4 gives recent European Best Practice Guidelines for the HD and PD patient nutritional follow-up [10,11]. Unstable and malnourished patients may require monitoring at shorter intervals. Severe malnutrition requiring nutritional intervention can be diagnosed by a decrease in BMI < 20, a body weight loss > 10% within 6 months, serum albumin <35 g/l and transthyretin <300 mg/l [62]. European best practice guidelines for nutritional parameter monitoring in haemodialysis (HD) and peritoneal dialysis (PD) patients [10,11] HD, haemodialysis; PD, peritoneal dialysis; BW, Body weight; BMI, Body mass index; nPNA, normalized protein equivalent of total nitrogen appearance. European best practice guidelines for nutritional parameter monitoring in haemodialysis (HD) and peritoneal dialysis (PD) patients [10,11] HD, haemodialysis; PD, peritoneal dialysis; BW, Body weight; BMI, Body mass index; nPNA, normalized protein equivalent of total nitrogen appearance. Recent studies showed that appetite assessment could be a simple and useful clinical tool in identifying dialysis patients at a risk of mortality [63]. In the absence of water retention, triceps skinfold thickness (TSF) can be useful to assess fat stores and arm muscle circumference (AMC = arm circumference − 3.14 × TSF) to assess muscle mass [64]. Body composition assessment using bioelectrical impedance analysis (BIA) and DEXA need to take into account the changes in body water compartments [65] (see associated paper in the same issue of the Journal). Handgrip strength was shown to be a marker of nutritional status, lean muscle mass and prognosis in dialysis patients [66,67]. Energy requirements given for HD and PD patients are 30–35 kcal/kg/day (Table 5) [8–11]. In malnourished HD patients, energy intakes of 22–24 kcal/kg/day have been reported. Thus, the calorie amount to be furnished by nutritional supplements is usually ~10 kcal/kg/day [41]. The caloric supply should be given according to the abnormalities of glucose metabolism and fat clearance. Fat calories should account for 30–40% of total energy supply. The addition of carnitine (0.5–1 g daily) has been proposed when plasma-free carnitine is reduced. Recommendations for protein and energy supply in adult patients on haemodialysis [8–10] and peritoneal dialysis (PD) [8–11] ESPEN, European Society of Parenteral and Enteral Nutrition; NKF, National Kidney Foundation; EBPG, European best practice guidelines; HD, haemodialysis; DP, peritoneal dialysis. Recommendations for protein and energy supply in adult patients on haemodialysis [8–10] and peritoneal dialysis (PD) [8–11] ESPEN, European Society of Parenteral and Enteral Nutrition; NKF, National Kidney Foundation; EBPG, European best practice guidelines; HD, haemodialysis; DP, peritoneal dialysis. The mean protein requirements for HD and PD patients are 1.2 g/kg/day in HD and 1.3 g/kg/day in PD patients, respectively (Table 5) [8–11]. Because no controlled data support the use of specific AA formulae, standard AA solutions are commonly used. Given the spontaneous intake reported in most of malnourished dialysis patients (0.8–1.0 g/kg/day), ~0.3 g protein/kg/day should be usually supplied by nutritional supplementation [41]. Phosphorus intake should be limited to 10–15 mg/kg/day. As phosphorus and protein are combined in nutrients in a ratio of 10–13 mg phosphorus/g protein, most HD patients who have an adequate protein intake will need phosphate binders. A renal dietician will be helpful to choose nutrients low in phosphorus. The usual recommendations for micronutrient supply are given in Table 6 [9]. Due to dialysis-induced losses, water-soluble vitamins should be supplied. Vitamin D analogues should be given according to serum calcium, serum phosphorus and serum parathyroid hormone [8]. The recent European Best Practice Guidelines (EBPG) also recommend to supply HD patients with thiamine, riboflavin, cobalamine, niacin, biotin, pentothenic acid and tocopherol (expert opinion) [10]. When large quantities of glucose are given, the common dietary intake of thiamine (0.5–1.5 mg/day) should be supplemented with a daily oral dose of 1–5 mg of thiamine hydrochloride [68]. Vitamin E may be of interest in high cardiovascular risk patients at the daily dose (alpha-tocopherol, 800 IU/day) [69]. Although routine HD does not induce significant trace element losses, in depleted patients, zinc and selenium supplementation may be useful. Micronutrient deficiency was reported to be more prevalent in anuric PD patients compared to patients with residual renal function. Thus, supplementation with water-soluble vitamins may be particularly indicated in anuric PD patients [70]. Recommendations for micronutrient supply in adult patients on haemodialysis and peritoneal dialysis [8–10] ESPEN, European Society of Parenteral and Enteral Nutrition; HD, haemodialysis; DP, peritoneal dialysis; PTH, parathormone. Recommendations for micronutrient supply in adult patients on haemodialysis and peritoneal dialysis [8–10] ESPEN, European Society of Parenteral and Enteral Nutrition; HD, haemodialysis; DP, peritoneal dialysis; PTH, parathormone. Few data are available concerning the usefulness of appetite stimuli in dialysis patients. The 16-week administration of megestrol acetate was reported to improve body weight, BMI, body fat, triceps skinfold and serum albumin [71]. Recently, a double-blinded randomized crossover study in a group of 12 malnourished dialysis patients has reported a significant increase of appetite after a treatment with daily subcutaneous ghrelin, showing that appetite manipulation may be a promising therapeutic strategy for malnutrition [72]. Nutritional support includes nutritional counselling, oral supplementation, intradialytic parenteral nutrition (IDPN) in HD patients, intraperitoneal parenteral nutrition (IPPN) in PD patients and enteral nutrition. The of both oral supplementation, and to improve protein metabolism during dialysis was recently demonstrated In malnourished CKD patients, these were shown to be to improve nutritional was reported to improve nutritional status in HD and PD patients These data for a dietician intervention in order to and spontaneous intakes and to oral nutritional supplements can and g of In HD patients, a with oral and enteral supplements showed an increase in serum albumin of g/l This addressed clinical in both malnourished and non-malnourished patients. Table the controlled studies in malnourished HD and PD patients Although these were the nutritional parameters were in the controlled in HD patients. in the and spontaneous feeding was reported in HD patients the use of in PD patients are In an a oral protein supplementation to improve nutritional parameters in PD patients, patients to to this treatment In a randomized clinical including both HD and PD patients, essential AAs supplementation nutritional in HD, but not in PD patients supplementation during 6 was reported to improve nutritional status A of studies that nutritional support in HD and PD patients with malnutrition protein energy HD, haemodialysis; DP, peritoneal dialysis; BMI, body mass index; BW, body weight; oral parenteral peritoneal amino amino serum amino standard amino triceps arm muscle normalized protein catabolism of of patients. A of studies that nutritional support in HD and PD patients with malnutrition protein energy HD, haemodialysis; DP, peritoneal dialysis; BMI, body mass index; BW, body weight; oral parenteral peritoneal amino amino serum amino standard amino triceps arm muscle normalized protein catabolism of of patients. The for the of are to a nutritional supplementation and not a to the of by a and in HD patients, to the protein associated with the dialysis Thus, the time for should be h after h after in the and at the of HD In HD patients, is a given three a through the of the dialysis The have been proposed in order to should be at a rate during dialysis should be increased from in a during the to a of should be associated with a controlled volume and 4 g should be of in order to due to In HD patients, energy supply should be discussed according to one the use of glucose is limited by glucose and the risk of the the that lipid is fat the in HD patients during the phase of fat supply are the essential fatty acid deficiency reported in HD patients the high ratio of fat and which well the lack of of fat on dialysis [62]. In more than 30 studies, including 5 controlled was shown to improve nutritional parameters (Table It be underlined that both oral supplementation and can only the equivalent of kcal/kg/day and g oral supplementation and only it possible to the levels of protein and energy intake when spontaneous oral intake are g protein and Because the oral is more and than the of has been are the of nutritional support on patient morbidity and The French addressed these [62]. and malnourished HD patients were to during a and followed up during 2 The two In both independent of serum protein, a in body mass serum albumin and transthyretin was obtained of the addition of Concordingly, not improve the survival rate obtained at model the response to nutritional as by the increase in serum transthyretin concentrations by mg/l within independently a decrease in the 2-year In patients, the increase in serum transthyretin was not associated with a better an was with data showing that survival of patients on HD was independent of nutritional status as by BMI, serum albumin and transthyretin [5]. These data showed the of in of both nutritional and outcome should be proposed only in HD patients with with or not When malnutrition is associated with spontaneous intake g protein and a daily nutritional support is to nutritional In these patients, enteral nutrition should be to studies addressed the use of enteral nutrition in dialysis patients. Enteral nutrition is most used when oral supplementation is not to nutritional requirements in conditions such as severe to or and and In these enteral nutrition in total enteral and Because the of enteral nutrition usually a is usually of the intraperitoneal administration of The analysis of studies of intraperitoneal AA including randomized showed an in nitrogen and nutritional parameters In malnourished PD patients, nitrogen serum and plasma AA pattern In a controlled PD patients were to one daily with AA or to with protein intake increased in the AA nPNA, albumin and decreased in the but or increased in the AA The nutritional in the AA group was more in This not a significant of on survival may be associated with and and close monitoring Most randomized studies the of nutritional support in malnourished HD and PD patients showed in nutritional parameters (Table It should be underlined that only one study demonstrated that the in nutritional status during nutritional therapy was associated with an outcome in of and survival [62]. The for nutritional support has been proposed according to patient nutritional assessment for nutritional support in HD and PD patients. BMI, body mass index; parenteral dialysis; enteral parenteral nutrition. In patients with malnutrition as by spontaneous intake, dietary counselling, should be In patients severe malnutrition, with spontaneous intake dietary and should be in HD or in is indicated in patients with can be when or are to improve nutritional In patients severe malnutrition, with spontaneous intake or in and are to nutritional supply and are not a daily nutritional support is and should be to is indicated when is or a nutritional intake of the levels of nutritional as by available is the usual of nutritional a of malnourished HD patients not to nutritional In these patients, the therapeutic include treatments to improve to decrease protein breakdown to protein synthesis. was demonstrated to improve protein synthesis and to increase muscle mass In a randomized controlled the of an increase in the muscle in an therapy and daily dialysis, which were demonstrated to improve nutritional status have been proposed in the [10]. to these in the of severe malnutrition to nutritional a of should be proposed in patients for should be weekly or patients should be at for in plasma liver and and patients with a should not Similarly, the proposed to a to of daily dialysis daily or long as a therapy in patients HD sessions with of malnutrition or malnourished patients with appetite after a nutritional [10]. factors may be another to improve nutritional of were shown to induce a positive nitrogen in PD patients with protein–energy malnutrition Similarly, the administration was reported to induce an increase in LBM and an in the In order to improve protein are such the use of essential AA and branched-chain supplements and the of inflammation by the by the administration of These data that a nutritional and may be the treatment for PEW during dialysis. It can be considered that PEW survival is found in of dialysis patients. the cause of malnutrition should be the of patient data that nutritional in the form of is to improve nutritional in HD patients, morbidity and mortality can be reduced when an in nutritional status, as by a transthyretin increase by 30 is obtained during nutritional support [62]. it is not known this is to patients PD administration of nutritional support and a of may improve the of nutritional The main for the treatment of PEW during dialysis may be the of specific for dialysis patients, a therapy including nutritional and the use of daily dialysis in HD patients. of interest
No takes yet. Share an insight, caveat, or question.
Heng et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: